Grants per year
- 375 - 400 out of 547 results
Search results
-
Prot #HGS1006-C1124: A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA™ (belimumab)
Hsieh, C. (PD/PI)
Outcome Sciences Inc., GlaxoSmithKline LLC
10/9/14 → 11/30/24
Project: Research project
-
Prot# IFN3958g: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single-and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults with Mildly Active Systemic Lupus Erythematosus
Ramsey-Goldman, R. (PD/PI)
8/16/07 → 8/16/10
Project: Research project
-
Prot# IFN3958g: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single-and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults with Mildly Active Systemic Lupus Erythematosus
Ramsey-Goldman, R. (PD/PI)
8/16/07 → 8/16/10
Project: Research project
-
Prot #IIS2017-10679: Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD using High Throughput Single-cell RNA-Seq
Gottardi, C. J. (PD/PI), Bhorade, S. M. (Co-PD/PI), Dematte D'Amico, J. E. (Co-Investigator), Hinchcliff, M. E. (Co-Investigator) & Lam, A. P. (Other)
Boehringer Ingelheim Pharmaceuticals, Inc.
12/28/17 → 12/28/24
Project: Research project
-
Prot# IM101-031-016: A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Use Study to Evaluate the Safety and Tolerability of BMS-188667 Administered Intravenously to Subjects with Active RA with or without Medic
Ruderman, E. M. (PD/PI)
Bristol-Myers Squibb Pharmaceutical Research Institute
1/9/03 → 9/11/10
Project: Research project
-
Prot# IM101042: A Phse IIB, Mlt-Cntr, Rndmzd, Dbl-Blnd, Plcb-Cntrlld Stdy to Evlt the Effccy & Sfty of Abatacept vs. Plcb on A Bckgrnd of Orl Glucocorticosteroids in the Trtmnt of Sbjcts w/ Systmc Lupus Erythematosus & the Prvnton of Sbsqnt Lupus Flare
Ruderman, E. M. (Co-PD/PI)
Bristol-Myers Squibb Pharmaceutical Research Institute
5/16/06 → 10/21/10
Project: Research project
-
Prot #IVXCpn001: Efficacy, Safety and Impact on Biomarkers of Ala-Chaperonin 10 In subjects with mildly active Systemic Lupus Erythematosus
Hsieh, C. (PD/PI)
5/23/14 → 5/23/17
Project: Research project
-
Prot #JBT101-DM-002: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Hsieh, C. (PD/PI)
1/22/19 → 2/22/23
Project: Research project
-
Prot #JBT101-LTS-001: An Observational Long-Term Safety Surveillance Study of Participants from Corbus Sponsored Lenabasum Pivotal Clinical Trials
Hsieh, C. (PD/PI)
9/15/20 → 9/15/23
Project: Research project
-
Prot# LBRA01: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B? Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Rheumatoid Arthritis (RA)
Ruderman, E. M. (PD/PI)
1/15/04 → 5/24/07
Project: Research project
-
Prot# LBRA01: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B? Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Rheumatoid Arthritis (RA)
Ruderman, E. M. (PD/PI)
1/15/04 → 5/24/07
Project: Research project
-
Prot# LBSL02: A Phs 2, Mlti-Cntr, Dbl-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, & Efficacy of LymphoStat-B? Antibody (Monoclonal Anti-BLyS Antibody) in Subjects w/Systemic Lupus Erythematosus (SLE)
Ramsey-Goldman, R. (PD/PI)
11/14/03 → 8/21/10
Project: Research project
-
Prot# LBSL02: A Phs 2, Mlti-Cntr, Dbl-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, & Efficacy of LymphoStat-B? Antibody (Monoclonal Anti-BLyS Antibody) in Subjects w/Systemic Lupus Erythematosus (SLE)
Ramsey-Goldman, R. (PD/PI)
11/14/03 → 8/21/10
Project: Research project
-
Prot# M02-537: A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients with Moderate to Severely Active Psoriatic Arthritis
Ruderman, E. M. (PD/PI)
PPD Development, Abbott Laboratories
9/24/03 → 9/11/10
Project: Research project
-
PROT# M10-883: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Peripheral Spondyloarthritis
Ruderman, E. M. (PD/PI)
5/14/10 → 5/14/13
Project: Research project
-
Prot# MA25522: A Randomized, Double-Blind, Parallel-Group Study Of The Reduction Of Signs And Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both In Combination With MTX, In Patients With Moderate To Severe Active Rheumatoid Arthritis And A
Ruderman, E. M. (PD/PI)
PharmaNet, Inc., Genentech, Inc
9/6/11 → 9/6/14
Project: Research project
-
Prot #NAV3-32: A Comparison of Tc 99m Tilmanocept Quantitative Imaging with Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue from Subjects Clinically Diagnosed with Rheumatoid Arthritis (RA)
Ruderman, E. M. (PD/PI)
Navidea Biopharmaceuticals, Inc.
2/5/21 → 8/4/25
Project: Research project
-
Prot #PCYC-1301-RA: A Randomized, Double-blind, Placebo-controlled Phase 1 Study of the Orally-administered Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-45466 with a Single Ascending Dose Phase in Healthy Subjects and a Multiple Ascending Dose Phase in Su
Ruderman, E. M. (PD/PI)
6/2/14 → 6/2/17
Project: Research project